Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative increase in stock price of over 20% compared to the benchmark index within the next six months [7][14]. Core Insights - The company reported a revenue of 1.56 billion yuan for 2024, representing a year-over-year growth of 13.4%, with a net profit of 161 million yuan, up 14.1% year-over-year. The fourth quarter of 2024 saw a significant revenue increase of 39% year-over-year [4][5]. - The company's online sales are driven by a major product, with e-commerce revenue growing by 52% year-over-year, indicating strong growth potential for 2025 [5]. - The gross profit margin for 2024 was 49.4%, an increase of 5.3 percentage points year-over-year, reflecting improved profitability [6]. - The company is expected to continue expanding its market share in oral care and beauty, with projected net profits of 200 million yuan, 252 million yuan, and 317 million yuan for 2025, 2026, and 2027 respectively [7][10]. Financial Summary - The latest closing price of the company's stock is 44.68 yuan, with a total market capitalization of 7.7 billion yuan [3]. - The company’s earnings per share (EPS) for 2024 is projected at 0.94 yuan, with a price-to-earnings (P/E) ratio of 47.73 [10][13]. - The company’s revenue is expected to grow to 1.89 billion yuan in 2025, with a growth rate of 21.3% [10][11].
登康口腔：大单品带动线上放量，毛销差优化-20250422